Drug
Efgartigimod Ph20
Efgartigimod Ph20: highest development phase Phase 3, developed by Argenx. 14 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efgartigimod PH20 SC NCT07570316 | Phase 3 | Graves' Disease |
| efgartigimod PH20 SC NCT04735432 | Phase 3 | Generalized Myasthenia Gravis |
| efgartigimod PH20 SC NCT05681481 | Phase 3 | Bullous Pemphigoid |
| efgartigimod PH20 SC NCT04598477 | Phase 3 | Pemphigus Vulgaris |
| efgartigimod PH20 SC NCT04812925 | Phase 3 | Primary Immune Thrombocytopenia |
| Efgartigimod PH20 SC NCT05979441 | Phase 3 | Myositis |
| Efgartigimod PH20 SC NCT06558279 | Phase 3 | Myasthenia Gravis, Ocular |
| Efgartigimod PH20 SC NCT06307613 | Phase 3 | Thyroid Eye Disease |
| efgartigimod PH20 SC NCT04818671 | Phase 3 | Generalized Myasthenia Gravis |
| efgartigimod PH20 SC NCT07596849 | Phase 3 | Graves Disease |
| Efgartigimod PH20 SC - prefilled syringe NCT06503731 | Phase 2 | Antibody-mediated Rejection |
| Efgartigimod PH20 (ARGX-113) SC NCT07583641 | Phase 2 | Autoimmune Encephalitis (AE) |
| Efgartigimod PH20 SC NCT06655155 | Phase 2 | Systemic Sclerosis (SSc) |
| Efgartigimod PH20 SC NCT04280718 | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Latest
No recent events.
Follow Efgartigimod Ph20 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.